THE SAFETY OF DRUGS FOR MENARINI

Menarini monitors the safety of a drug even after it’s marketed, from the time a drug is prescribed by the physicians up to the time it’s used by the patient (and even later).
This monitoring is done through an essential instrument, Pharmacovigilance, which takes care of identifying, evaluating, understanding and preventing any type of any safety problem that may occur following the use of a drug.

In the Menarini Group, the Pharmacovigilance Department consists of more than 200 people, graduated in scientific matters in the majority of cases, often physicians.

For all the drugs marketed by Menarini in the world, all possible information about any problem resulting from the use of a drug, identified as a possible adverse event, is collected through safety reports.
These reports can be made by healthcare operators (physicians, nurses, pharmacists) or by the patients themselves.

To give an example:

1 -The patient takes a drug and has a problem.

2 -He/she can easily refer this to his/her doctor who in turn reports this to the Health Authorities or directly to us in the Company.

3 -The reports received by the Company are handled by the Pharmacovigilance Department and managed entering the information included in the report in a safety database in close correlation with the database of the European Medicines Agency.

4 -All the information contained in this database is constantly analysed in order to identify and prevent any problems regarding the that may occur following the use of a drug.

We do all this to safeguard the patient’s health and safety.

Yellow Card

Adverse events should be reported. 

Reporting forms and information can be found at http://www.eof.gr or search for MHRA Yellow Card in Google Play or Apple App Store. 

Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL. Phone (+30) 210 8316111-13